› 1fvt

X-ray diffraction
2.2Å resolution

THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR

Released:
DOI: 10.2210/pdb1fvt/pdb
PDB entry 1fvt coloured by chain, front view.
PDB entry 1fvt coloured by chain, side view.
PDB entry 1fvt coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors.
Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT, Griffin RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, Knick VB, Lackey K, Lovejoy B, Luzzio MJ, Murray D, Parker P, Rocque WJ, Shewchuk L, Veal JM, Walker DH, Kuyper LF
Science 291 134-7 (2001)
PMID: 11141566

Function and Biology Details

Reaction catalysed: 
ATP + a protein = ADP + a phosphoprotein
Biochemical function:
Biological process:
Cellular component:
Sequence domains:
Structure domain:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-150313 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Cyclin-dependent kinase 2 Chain: A
Molecule details ›
Chain: A
Length: 298 amino acids
Theoretical weight: 33.98 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P24941 (Residues: 1-298; Coverage: 100%)
Gene names: CDK2, CDKN2
Sequence domains: Protein kinase domain
Structure domains:

Ligands and Environments

1 bound ligand:
Ligand 106 1 x 106
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: RIGAKU
Spacegroup: P212121
Unit cell:
a: 54.142Å b: 72.711Å c: 72.933Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.195 0.232 0.232
Expression system: Escherichia coli

Quick links

Citations

29 review citations

GSK3 takes centre stage more than 20 years after its discovery.
Frame et al. (2001)
28 more

6 mentions without citation

In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug.
Shi et al. (2015)
5 more